tm logo
APDUCE
Live/Registered
REGISTERED

on 26 Sep 2023

Last Applicant/ Owned by

SUZHOU INDUSTRIAL PARK, SUZHOU

JIANGSU

CN

215000

Serial Number

97412748 filed on 16th May 2022

Registration Number

7172959 registered on 26th Sep 2023

in the Principal Register

Correspondent Address

Kathryn E. Smith

Wood Herron & Evans LLP

600 Vine Street

Suite 2800

Cincinnati, OH 45202

Filing Basis

1. intent to use

Disclaimer

NO DATA

APDUCE

Chemical preparations for medical purposes, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs sold in bulk, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases,Read More

Classification Information


Class [005]
Pharmaceutical Products


Chemical preparations for medical purposes, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs sold in bulk, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; radioactive substances for medical purposes; gases for medical purposes, namely, nitric oxide for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; media for bacteriological cultures; medicated sweets; dietetic preparations adapted for medical use; depuratives for the body; diagnostic preparations for veterinary purposes; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets

Mark Details


Serial Number

No 97412748

Mark Type

No Service/Collective Mark

Attorney Docket Number

No ASCNT-20128

44D Filed

Yes

44D Current

No

44E filed

No

44E Current

Yes

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
26th Sep 2023REGISTERED-PRINCIPAL REGISTER
26th Sep 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
11th Jul 2023PUBLISHED FOR OPPOSITION
11th Jul 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21st Jun 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05th Jun 2023LAW OFFICE PUBLICATION REVIEW COMPLETED
27th May 2023EXAMINERS AMENDMENT -WRITTEN
27th May 2023EXAMINERS AMENDMENT E-MAILED
27th May 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27th May 2023EXAMINER'S AMENDMENT ENTERED